Track topics on Twitter Track topics that are important to you
CP Merritt, a purebred Arabian, was treated with VetStem Regenerative Cell Therapy in 2007 for cartilage degeneration in his fetlock by Dr. John McCarroll of Equine Medical Associates. Over ten years after treatment with stem cells, Merritt is still competing and winning. POWAY, Calif. (PRWEB) December 18, 2018 CP Merritt is a national champion Arabian horse that currently competes in Second Leve...
Lilly is battling for market share against Novartis' rival IL-17 inhibitor Cosentyx, and hopes a study pitting Taltz against Humira can help.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the initiation of Codex, the Company's pivotal Phase 2 study of inodiftagene vixteplasmid (BC-819), a first-in-class gene thera
NewsNew study shows how newly created cardiac muscle cells can be made to pump together.Contributed Author:
In this month's installment of Ask the PI, ONCOLOGY spoke with two authors of the study, Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists.
Eli Lilly's Taltz shows superiority in head-to-head study versus AbbVie's Humira in active psoriatic arthritis https://www.firstwordpharma.com/node/1611923 $LLY
Eli Lilly and Co. (LLY) said Monday that Taltz, or ixekizumab, met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira, or adalimumab, in patients with active psoriatic arthritis or PsA who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive.
The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019. CAR T Cell Therapy is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases. The recent approvals of the first CAR T Cell treatmen...
At 24 weeks, the study met its primary endpoint. Lilly's Taltz demonstrated superiority against AbbVie's Humira, the best-selling drug in the world, in improving the signs and symptoms of active PsA.
As shown in this video from Cell, a team of researchers was able to produce skeletal muscle stem cells from pluripotent stem cells using teratoma formation–without genetic manipulation. The study shows that these cells can regenerate up to 80% muscle volume. The post Functional Skeletal Muscle Stem Cells Created from PSCs appeared first on GEN - Genetic Engineering and Biotechnology News.
While obesity has been shown to increase the risk of developing gestational diabetes mellitus (GDM) and preeclampsia (PE) in pregnancy, the association between metabolic syndrome and adverse pregnancy outcomes has not been investigated. In this multicenter prospective cohort study, 5,530 nulliparous women with singleton pregnancies recruited between November 2004 and February 2011 were followed up...
Psoriatic Arthritis Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Psoriatic Arthritis Global Clinical Trials Review, H1, 2018" provides an overview of Psoriatic Arthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Psoriatic Arthritis. Report includes an overview of trial numbers and their average enrollment in...
NewsResearchers have keyed into the biological mishap that causes stunted brain growth and muscle movement failure.
NMD Pharma, our pick of this week, is based in Aarhus, Denmark. The company is flexing its muscles to develop a drug that can treat muscle weakness in orphan neuromuscular disorders such as amyotrophic lateral sclerosis and myasthenia gravis. ... The post This Company is Strengthening Muscles in Neuromuscular Disorders appeared first on Labiotech.eu.
As brain disorders such as Alzheimer’s disease, autism and depression increase in frequency, the synergistic fields of neurology and psychiatry may illuminate important clues that can lead to innovative treatments for these conditions.
Short Bowel Syndrome Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Short Bowel Syndrome Global Clinical Trials Review, H2, 2018" provides an overview of Short Bowel Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Short Bowel Syndrome. Report includes an overview of trial numbers and their average enrollmen...
Corcept Therapeutics (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs from the class of medications known as strong CYP3A inhibitors to treat patients with hypercortisolism (Cushing’s syndrome). The patent will expire in 2037. As quoted in … Continued The post ...
Irritable bowel syndrome, IBS, is a gastrointestinal disorder that affects approximately 12 percent of the U.S. population. For individuals who suffer from this condition, it... Read More →
Zynerba Pharmaceuticals (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is reporting new 12-month open label clinical data describing the long term impact of ZYN002 on emotional and behavioral symptoms of Fragile X Syndrome (FXS) in a poster presentation at the 57th Annual Meeting of the American...
What is the most common risk factor for Guillain-Barré Syndrome? Plus 4 other quick questions to test your knowledge.
Junius Moore, 35, will become the world’s first recipient of an osseointegrated LUKE arm combined with post targeted muscle reinnervation (TMR) surgery. This first-of-its-kind prosthetic advancement will pave The post Next Step Bionics announces breakthrough advancement in use of LUKE arm prosthesis appeared first on Compelo Medical Devices.
AMRA Medical stated that AMRA Profiler can be used for non-invasive fat and muscle evaluation that enables the generation, display and review of MR-based body composition measurements. AMRA The post AMRA Medical secures FDA approval for AMRA Profiler appeared first on Compelo Medical Devices.